Skip to main content
Premium Trial:

Request an Annual Quote

BioTheranostics, Ferrer InCode Ink Distribution Pact

NEW YORK (GenomeWeb News) – BioMerieux subsidiary BioTheranostics said today that it has signed up Spain's Ferrer InCode to market its molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.

Under the agreement, Ferrer InCode will market BioTheranostics’ Theros CancerTYPE ID molecular cancer classifier. The test is a 92-gene assay that oncologists may use in their efforts to manage patients whose primary tumor sites are not known, otherwise known as cancers of unknown primary origin, or CUP.

BioTheranostics said that around three to five percent of cancers diagnosed worldwide are classified as CUP, which can cause doctors difficulties in trying to develop their treatment plans.

Ferrer InCode, the biotech subsidiary of Grupo Ferrer International, plans to begin marketing the tests immediately, BioTheranostics said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.